Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 24-week, Multicenter, Randomized, Open-Label, Parallel-group StudyComparing the Efficacy and Safety of Toujeo® and Tresiba® in Insulin-NaivePatients With Type 2 Diabetes Mellitus Not Adequately Controlled With OralAntihyperglycemic Drug(s) ± GLP-1 Receptor Agonist
Brief Summary: Primary Objective:

To demonstrate the noninferiority in the efficacy of Toujeo® to Tresiba® in glycated hemoglobin (HbA1c) change from Baseline to Week 24.

Secondary Objectives:

Change From Baseline in HbA1c to Week 12

To assess the effects of the insulin Toujeo® in comparison with insulin Tresiba® at week 12 and week 24 on:

* Change in Fasting plasma glucose (FPG);
* Change in Fasting self-monitored plasma glucose (SMPG) and 4-point SMPG and 8-point SMPG profile;
* Percentage of participants reaching HbA1c targets \<7% or ≤6.5%;
* Percentage of participants reaching HbA1c targets \<7% or ≤6.5% without severe and/or confirmed hypoglycemia
* Frequency of occurrence and diurnal distribution of hypoglycemia by American Diabetes Association (ADA) category of hypoglycemia.

To assess the safety in each treatment group.

To assess the treatment effects in each treatment group on Patient Reported Outcomes (PRO).

Percentage of participants requiring rescue therapy.


Options:
A: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: Insulin glargine, 300U/mL, Drug: Non-insulin anti-diabetic treatment | Arm Label: Tresiba; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin degludec, 100 U/mL, Drug: Non-insulin anti-diabetic treatment | Intervention Type: DRUG; Name: Insulin glargine, 300U/mL; Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: Insulin degludec, 100 U/mL; Assigned to Arm(s): Tresiba | Intervention Type: DRUG; Name: Non-insulin anti-diabetic treatment; Assigned to Arm(s): Toujeo, Tresiba
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine (HOE901) [Lantus], Drug: Glimepiride | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: human insulin [NPH] | Intervention Type: DRUG; Name: Insulin Glargine (HOE901) [Lantus]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: human insulin [NPH]; Assigned to Arm(s): 2
C: Arm Label: Toujeo; Type: EXPERIMENTAL; Interventions: Drug: insulin glargine (U300) | Arm Label: "Standard of care" commercially available basal insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin glargine (U100), Drug: NPH insulin, Drug: insulin detemir, Drug: insulin degludec | Intervention Type: DRUG; Name: insulin glargine (U300); Assigned to Arm(s): Toujeo | Intervention Type: DRUG; Name: insulin glargine (U100); Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: NPH insulin; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): "Standard of care" commercially available basal insulin | Intervention Type: DRUG; Name: insulin degludec; Assigned to Arm(s): "Standard of care" commercially available basal insulin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Intervention Type: DRUG; Name: Insulin Glargine (HOE901)/NPH Insulin; Assigned to Arm(s): 1, 2

Answer: A